CONTEXT

The critical position of Spleen Tyrosine Kinase (Syk) upstream to immunoreceptor signaling complexes that regulate inflammatory responses in leukocytes suggests that it could be an excellent target for treating allergic disorders. Pharmacological inhibitors of Syk kinase activity bearing therapeutic potential have been developed. However, inhibiting the catalytic activity of this kinase leads to unwanted consequences of on various physiological functions such as cell differentiation, adhesion and proliferation. Thus there is still a need in developing new approaches for the discovery of a novel class of safer and yet effective Syk inhibitors.